左-卡尼汀对Ⅱ型糖尿病患者血浆细胞间粘附分子-1的影响

Effect of L-carnitine on intercellular adhesion molecule-1 at Type II diabetes patients

目的观察左 卡尼汀对Ⅱ型糖尿病患者可溶性细胞间粘附分子 1(sICAM 1)的影响。方法 4 3例Ⅱ型糖尿病患者随机分为实验组 (n =2 2 ,每日静脉滴注左 卡尼汀 3g ,连续 14d)和对照组(n =2 1,除不应用左 卡尼汀外 ,其它治疗同实验组 ) ,动态监测治疗前后血浆中sICAM 1的水平变化。结果治疗前两组sICAM 1水平无显著差异 (P >0 .0 5 ) ;治疗后第 7d ,实验组sICAM 1与对照组比较P <0 .0 5 ;治疗后第 14d ,实验组sICAM 1明显低于对照组 (P <0 .0 1)。两组患者血浆sICAM 1治疗后均低于治疗前 (P <0 .0 5或P <0 .0 1)。结论左 卡尼汀由于能促进脂肪燃烧氧化 ,使机体获得足够的能量 ,降低糖原转化为葡萄糖的速度 ,从而降低患者的血糖浓度 ;此外 ,左 卡尼汀能降低患者血浆sICAM 1水平 ,其可能的机制是左 卡尼汀阻止了患者体内非酶糖化产物形成过程中细胞因子、氧自由基等的产生。

Objective To investigate the effects of L-carnitine on treatment of Type II diabetes patients for intercellular adhesion molecule-1 (ICAM-1). Methods 43 cases with Type II diabetes patients were selected randomly and 22 cases treated with L-carnitine of 3g/day for intravenous drip, 21 cases were selected as control group. The treatment for the test group was a fourteen-day course of one dose a day. All of patients were tested for plasma adhesion molecule-1. Results There was no obvious difference of changes in adhesion molecule-1 on treatment before, but it was obvious difference on the seventh day of after theatment (P<0.05) and the fourteenth day (P<0.01) between the both groups. Conclusion L-carnitine has a good and safe effect on treating Type II diabetes at reducing blood intercellular adhesion molecule-1, the mechanism is probably due to L-carnitine resulting in lowered levels of cytokine.